Co-promotion of products (other than Lipitor) by the Pfizer and Parke-Davis sales forces will begin by the end of the year, Pfizer's Katen reported. "At this moment we are cross-training our field organizations." The co-promotions "will be extensive, especially in CNS and cardiovascular." Pfizer has about 8,000 sales reps following the Warner-Lambert merger
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth